When Teladoc Health announced its financial results late last month, the results were eye-popping. The company reported revenue that grew 109% year over year. Excluding one-time charges, Teladoc cut is net loss by half. Yet in the wake of these seemingly impressive results, the stock sold off more than 19% in the days that followed.
In this Earnings Review that aired on Fool Live on Oct. 30, Fool.com contributors Danny Vena, Daniel Sparks, and Jason Hall discuss the market’s reaction to Teladoc’s earnings and the close of its merger with Livongo Health — and why the market got it wrong.
Jason Hall: “Which tech stock did the market get most wrong in its reaction to earnings?” Do either of you have an immediate reaction to that, or do you want to think about it a little bit more?
Danny Vena: I have an immediate reaction.
Hall: Danny, go ahead.
